Clinical Trials
4 trialsNCT04001777 2025-10-01
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
Ascentage Pharma Group Inc.
Phase 1 Active not recruiting
NCT03080311 2022-07-12
A Study of APG-1252 in Patients With SCLC or Other Solid Tumors
Ascentage Pharma Group Inc.
Phase 1 Completed
NCT04210037 2022-07-12
Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT03387332 2021-08-27
APG-1252 in Patients With SCLC or Advanced Solid Tumors
Ascentage Pharma Group Inc.
Phase 1 Terminated